We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




High Sensitivity ELISA Diagnoses Wegener's Granulomatosis

By Biotechdaily staff writers
Posted on 02 Oct 2007
Wegener's granulomatosis can now be diagnosed using a high sensitivity (hs) enzyme-linked immunosorbant assay (ELISA).

A fatal disease of unknown etiology, Wegener's granulomatosis is characterized by granuloma in the inflamed tissues of the respiratory tract, systemic vasculitis of small blood vessels, and glomerulonephritis. More...
Anti-neutrophil cytoplasmatic antibodies (ANCA) against cytoplasmic components of neutrophil granulocytes are diagnostic markers for the disease.

Antibodies against proteinase 3 (PR3) distinguish Wegener's granulomatosis from other ANCA-associated small vessel vasculitides such as microscopic polyangiitis and Churg-Strauss syndrome. Currently, diagnosis combines indirect immunofluorescence with an antigen-specific ELISA.

A study of patients with Wegener's granulomatosis--confirmed by clinical data and biopsy results--showed that the Anti-PR3 hs ELISA had a sensitivity of 96% and specificity of 99%. The ELISA is produced by Orgentec Diagnostika (Mainz, Germany) and the results correlated perfectly with indirect immunofluorescence but were superior to immunoblot, direct, and capture ELISA.

Although sera of patients with confirmed Wegener's granulomatosis had negative results for proteinase 3 autoantibodies when tested by the conventional direct ELISA, this assay detected PR3 antibodies in 71% of these sera.

Anti-PR3 hs ELISA detects patients with localized Wegener's granulomatosis corresponding to an early stage of the disease. Due to its sensitivity, high specificity, and excellent correlation with the immunofluorescence test (IFT), the assay replaces the need for complex analysis and significantly simplifies diagnosis of ANCA.

Orgentec Diagnostika develops, produces, and distributes tests for autoimmune diagnostics. Among these tests are methods for diagnosis and therapy monitoring of rheumatic diseases, vasculitis, diabetes and autoimmune disorders of the gastrointestinal tract.


Related Links:
Orgentec Diagnostica

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.